GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Bicycle Therapeutics
Bicycle Therapeutics is developing a new class of drugs based on bicyclic peptides. Its stock price represents a venture bet on its unique scientific platform. The chart reflects high volatility associated with news of clinical trials and partnerships with major pharma.
Share prices of companies in the market segment - Oncology platforms
Bicycle Therapeutics is a biotechnology company developing a new class of drugs based on bicyclic peptides for the treatment of cancer and other serious diseases. We classify it as an "Oncology Platform." The chart below shows the overall dynamics of this cutting-edge biotechnology segment.
Broad Market Index - GURU.Markets
Bicycle Therapeutics is a biotech company developing a new class of drugs based on bicyclic peptides for the treatment of cancer. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how investors are valuing this breakthrough technology.
Change in the price of a company, segment, and market as a whole per day
BCYC - Daily change in the company's share price Bicycle Therapeutics
Shares of Bicycle Therapeutics, an oncology company, exhibit high volatility, as measured by change_co. This reflects sensitivity to news about clinical trials. This metric is important for biotech sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology platforms
Bicycle Therapeutics plc is an oncology company. This chart illustrates the extreme volatility of the biotech sector. Comparison with BCYC's performance, with its unique platform, helps to assess it as a high-risk, clinical-data-dependent asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Bicycle is a biopharmaceutical company developing a new class of drugs (bicyclic peptides). This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Bicycle's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Bicycle Therapeutics
Bicycle Therapeutics's performance is a bet on a new technological platform in oncology. The company's annual market capitalization fluctuates depending on news about its "bicyclic peptides." Successful early clinical trial data and partnerships with major pharmaceutical companies are fundamental factors determining its valuation.
Annual dynamics of market capitalization of the market segment - Oncology platforms
Bicycle Therapeutics plc is a biotechnology company developing a new class of drugs based on bicyclic peptides. Its innovative platform is its key advantage. Its stock price reflects the high potential of its technology and the risks associated with clinical trials.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bicycle Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its innovative platform trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Bicycle Therapeutics
Bicycle, a biopharmaceutical company, has a speculative market cap. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its oncology drugs based on its unique "bicycle peptide" technology, which determines its future.
Monthly dynamics of market capitalization of the market segment - Oncology platforms
Bicycle Therapeutics is developing a new class of drugs called "bicyclic peptides" for the treatment of cancer and other serious diseases. This is an innovative platform with great potential. The chart below shows the overall dynamics in the oncology platform sector, where investors are searching for the next breakthrough technologies in the fight against cancer.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks developing new classes of drugs are a venture capital bet on science. The chart below shows investors' overall risk appetite. Is Bicycle Therapeutics moving at an extreme amplitude, amplifying market movements multiple times?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Bicycle Therapeutics
Bicycle Therapeutics, which is developing a new class of drugs called "bicycles," is experiencing high volatility. Its weekly stock price is reflecting clinical trial data and partnerships with major pharmaceutical companies.
Weekly dynamics of market capitalization of the market segment - Oncology platforms
Bicycle Therapeutics operates in the revolutionary sector of drug development, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can lift the entire segment. The chart will show whether the market perceives BCYC as a leader in this movement or simply part of it.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Bicycle Therapeutics, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how BCYC shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
BCYC - Market capitalization of the company Bicycle Therapeutics
Bicycle Therapeutics' chart is a visualization of its innovative approach to drug discovery. The company develops "bicyclic peptides" that combine the benefits of small molecules and antibodies. Its market capitalization dynamics reflect investors' bets on this unique platform and its potential in oncology and other fields.
BCYC - Share of the company's market capitalization Bicycle Therapeutics within the market segment - Oncology platforms
Bicycle Therapeutics is developing a new class of drugs called "bicycles" for targeted toxin delivery to tumors. Its share of the market capitalization of its oncology segment reflects the breakthrough potential of its platform. The chart below illustrates the valuation volatility inherent in biotech companies during clinical trials.
Market capitalization of the market segment - Oncology platforms
Bicycle Therapeutics is developing a new class of drugs, "bicycles," for targeted delivery of toxins to tumor cells. The chart below shows the market capitalization of these oncology platforms. This represents the valuation of one of the most advanced technologies in the fight against cancer, combining precision and potency.
Market capitalization of all companies included in a broad market index - GURU.Markets
Bicycle Therapeutics is a biotech company developing a new class of drugs based on bicyclic peptides, which combine the properties of small molecules and antibodies. The company's market capitalization is a bet on its unique platform. Its stake in the pharmaceutical industry is the weight of its innovative approaches that could enable the treatment of cancer and other diseases in entirely new ways.
Book value capitalization of the company, segment and market as a whole
BCYC - Book value capitalization of the company Bicycle Therapeutics
Bicycle Therapeutics' book value is a unique scientific platform. It consists of patents for "bicyclic peptide" technology, which combines the properties of small molecules and antibodies, and funds for clinical trials of oncology drugs. The chart below shows how the company is building a financial foundation for its breakthrough technology.
BCYC - Share of the company's book capitalization Bicycle Therapeutics within the market segment - Oncology platforms
Bicycle Therapeutics relies on its R&D laboratories to develop a new class of drugs. This scientific infrastructure is its key tangible asset. The S_BCap_Seg chart shows its share of physical assets in the innovative oncology platform sector.
Market segment balance sheet capitalization - Oncology platforms
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Bicycle Therapeutics, as a development company, has a more streamlined model. Its value lies in its unique scientific platform, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Bicycle Therapeutics is developing a new class of drugs based on "bicyclic peptides," which combine the properties of small molecules and antibodies. The company's assets comprise a unique scientific platform. The chart below illustrates the material weight behind this innovative "bicycle" technology in pharmaceuticals.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Bicycle Therapeutics
Bicycle Therapeutics' balance sheet is its unique scientific platform. The market values it at a huge premium, seeing its "bicyclic peptides" as a revolutionary approach to drug development. The chart shows how much this "faith in the technology" exceeds the value of its tangible assets.
Market to book capitalization ratio in a market segment - Oncology platforms
Bicycle Therapeutics is a biotech company developing a new class of drugs (bicyclic peptides) for the treatment of cancer. Its value lies in this unique platform. This chart shows how the market valuation, based on expectations of success, is a multiple of its book value.
Market to book capitalization ratio for the market as a whole
Bicycle Therapeutics is a biotech company developing a new class of drugs based on "bicyclic peptides." This is a breakthrough scientific platform. The company's value is based almost entirely on the potential of this technology. The chart vividly illustrates how the market is betting on a future revolution in pharmaceuticals by valuing intellectual property.
Debts of the company, segment and market as a whole
BCYC - Company debts Bicycle Therapeutics
Bicycle Therapeutics, a biotech company developing a new class of drugs (bicyclic peptides), uses raised capital to fund its clinical programs. This chart shows how the company spends funds to advance its innovative platform in oncology and other areas, which requires significant investment in science.
Market segment debts - Oncology platforms
Bicycle Therapeutics is developing a new class of drugs called "bicycles" for the treatment of cancer and other diseases. It is an innovative biotech platform. This chart shows how the company's debt load reflects its capital needs to fund clinical trials and prove the effectiveness of this cutting-edge therapeutic technology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Bicycle Therapeutics
Bicycle Therapeutics is developing a new class of drugs based on bicyclic peptides. This innovative platform requires significant funding during the research stage. This chart shows how much of its breakthrough, yet risky, developments the company is financing with debt.
Market segment debt to market segment book capitalization - Oncology platforms
Bicycle Therapeutics, a biotech company developing a new class of drugs called "bicyclic peptides" for the treatment of cancer and other diseases, compares its debt load to the overall market capitalization of the entire sector. It shows how the company finances its unique and innovative scientific platform.
Debt to book value of all companies in the market
Bicycle Therapeutics is a biotech company developing a new class of drugs—bicyclic peptides. This innovative platform requires significant investment in R&D. This chart of total market debt provides insight into the availability of capital needed to conduct clinical trials and prove the efficacy of this new technology.
P/E of the company, segment and market as a whole
P/E - Bicycle Therapeutics
This chart for Bicycle Therapeutics, a biotech company developing a new class of drugs based on bicyclic peptides ("Bicycles"), shows the high valuation of its innovative platform. There is no profit. The high valuation reflects investors' faith in the potential of this technology for targeted drug development, particularly in oncology.
P/E of the market segment - Oncology platforms
Bicycle Therapeutics is a biotech company developing a new class of drugs called "bicycles," which are synthetic peptides capable of delivering toxins to tumors. This chart illustrates the average valuation in the oncology platform sector, where investors are betting on innovative approaches to targeted cancer therapy.
P/E of the market as a whole
Bicycle Therapeutics is a biotech company developing a new class of drugs based on bicyclic peptides ("Bicycles") for the treatment of cancer and other diseases. This chart shows the overall risk appetite in the biotech sector. Comparisons with it allow us to see how much the company's valuation depends on faith in its revolutionary scientific platform rather than on overall market sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Bicycle Therapeutics
The chart for Bicycle Therapeutics, a biopharmaceutical company with a unique drug discovery platform, shows market expectations for its clinical development pipeline. It reflects investor confidence in the potential of its bicycle technology to create a new class of drugs, particularly in oncology.
%20P%2FE%20Bicycle%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Bicycle-Therapeutics&v=1772513720613 "Chart of the company's future (projected) P/E Bicycle Therapeutics")
Future (projected) P/E of the market segment - Oncology platforms
Bicycle Therapeutics plc is developing a new class of drugs, called "bicycles," for targeted therapy delivery to tumors. This chart shows average expectations for the biotech sector. BCYC's position may indicate the extent to which investors believe in its unique and proprietary technology platform for developing new cancer treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-platforms&v=1772513720636 "Future (projected) P/E graph of the market segment - Oncology platforms")
Future (projected) P/E of the market as a whole
Bicycle Therapeutics is developing a new class of drugs based on bicyclic peptides. For such an innovative biotech company, the overall market sentiment shown in this chart is important primarily for attracting investment to continue expensive research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513720665 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Bicycle Therapeutics
Bicycle Therapeutics is a biotech company developing a new class of drugs called "bicycles" for the treatment of cancer and other serious diseases. This chart reflects cutting-edge scientific research. The losses represent investments in R&D, while the potential profit explosion depends on the clinical success of this unique therapeutic platform.
Profit of companies in the market segment - Oncology platforms
Bicycle Therapeutics plc is developing a new class of drugs called "bicycles" for the treatment of cancer and other diseases. Profitability in the oncology platform sector, as this chart shows, is driven by the potential of breakthrough technologies. The BCYC platform could enable the creation of more precise and less toxic drugs, attracting the attention of investors and major pharmaceutical partners.
Overall market profit
Bicycle Therapeutics is developing a new class of drugs based on bicyclic peptides. The company is at the forefront of biotechnology, and its success is determined by scientific breakthroughs. The overall economic situation, shown in this chart, does not directly affect demand for its drugs, but it is critical for attracting investment for lengthy and expensive clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Bicycle Therapeutics
Bicycle Therapeutics is developing a new class of drugs, "bicycles," for the treatment of cancer and other diseases. This chart reflects analyst forecasts, which are bets on the success of this innovative platform in clinical trials. It represents the financial expression of hopes for a breakthrough in targeted therapy.
%20profit%20of%20the%20company%20Bicycle%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Bicycle-Therapeutics&v=1772513720904 "Graph of future (projected) profit of the company Bicycle Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology platforms
Bicycle Therapeutics is developing a new class of drugs based on bicyclic peptides that combine the best properties of small molecules and antibodies for the treatment of cancer and other diseases. This chart shows the revenue forecast for biotech platforms, reflecting market expectations for breakthrough therapeutic approaches and their commercial potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-platforms&v=1772513720927 "Graph of future (predicted) profits of companies in a market segment - Oncology platforms")
Future (predicted) profit of the market as a whole
Bicycle Therapeutics is developing a new class of drugs based on bicyclic peptides. Like most clinical-stage biotech companies, its valuation is determined by scientific data, not economics. However, the projected total profit is critical to assessing investors' risk appetite, which determines the company's ability to fund its research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513720929 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Bicycle Therapeutics
Bicycle Therapeutics is developing a new class of drugs called "bicycles," which combine the properties of small molecules and antibodies for targeted cancer treatment. Its revenue is generated through partnerships. The chart shows that investors value the potential of its unique scientific platform for developing breakthrough drugs, rather than current revenue.
P/S market segment - Oncology platforms
Bicycle Therapeutics is a pioneer in developing a new class of drugs based on bicyclic peptides for the treatment of cancer and other diseases. The chart shows the average revenue valuation in the biotech industry. It allows one to assess the premium investors are placing on the company for its innovative scientific platform compared to the industry average.
P/S of the market as a whole
Bicycle Therapeutics is developing a new class of drugs called "bicycles," which combine the properties of antibodies and small molecules for targeted cancer treatment. This is cutting-edge science. A graph of average market revenue estimates clearly demonstrates that investors are investing not in revenue, but in the potential of a completely new therapeutic platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Bicycle Therapeutics
Bicycle Therapeutics is a biotech company developing a new class of drugs called "bicycles" for the treatment of cancer and other diseases. The chart reflects the valuation of its innovative platform. The value is determined based on projected future revenues that could be generated if its unique drugs are successful.
%20P%2FS%20Bicycle%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Bicycle-Therapeutics&v=1772513721154 "The graph of the company's future (projected) P/S Bicycle Therapeutics")
Future (projected) P/S of the market segment - Oncology platforms
Bicycle Therapeutics is developing a new class of drugs based on bicyclic peptides (Bicycles®) for the treatment of cancer and other diseases. This chart shows the average estimated future sales for these oncology platforms. It helps understand how highly the market values the potential of this innovative technology and its ability to create effective drugs.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-platforms&v=1772513721282 "Future (projected) P/S market segment graph - Oncology platforms")
Future (projected) P/S of the market as a whole
Bicycle Therapeutics is a biotech company with a unique platform for developing a new class of drugs. Its value lies in the potential of its technology. This graph of overall revenue expectations is irrelevant. Investors are focused entirely on clinical trial results, which can create enormous value regardless of the economic climate.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513721467 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Bicycle Therapeutics
Bicycle Therapeutics is a biotech company developing a new class of drugs called "Bicycles®" for the treatment of cancer and other diseases. The revenue in this chart likely comes from payments from major pharmaceutical partners. These revenues validate the potential of its unique platform and fund further research.
Sales of companies in the market segment - Oncology platforms
Bicycle Therapeutics is a biotech company developing a new class of drugs called "bicyclic peptides," or "Bicycles." These molecules combine the benefits of small molecules and antibodies, allowing them to effectively penetrate tumors. This chart shows the total revenue for the sector, reflecting progress in creating innovative oncology platforms.
Overall market sales
Bicycle Therapeutics is a biotech company developing a new class of drugs based on bicyclic peptides for the treatment of cancer. This chart shows the state of the economy, but for BCYC, scientific progress is paramount. Its platform can create drugs that combine the properties of small molecules and antibodies. The company's value is determined by the potential of this unique technology.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Bicycle Therapeutics
Bicycle Therapeutics is developing a new class of drugs called "bicycles" for targeted toxin delivery to cancer cells. The company's future depends on the success of this innovative platform in the clinic. This chart visualizes market expectations regarding the potential of this unique technology in oncology.
%20sales%20of%20the%20company%20Bicycle%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Bicycle-Therapeutics&v=1772513721850 "Schedule of future (projected) sales of the company Bicycle Therapeutics")
Future (projected) sales of companies in the market segment - Oncology platforms
Bicycle Therapeutics is developing a new class of drugs called "bicycles" for the treatment of cancer and other serious diseases. This technology combines the advantages of small molecules and antibodies. The graph shows the prognosis for these oncology platforms. This is cutting-edge science, and the company's success depends on the results of clinical trials.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-platforms&v=1772513721908 "Schedule of future (projected) sales of companies in the market segment - Oncology platforms")
Future (projected) sales of the market as a whole
Bicycle Therapeutics is developing a new class of drugs based on bicyclic peptides for the treatment of cancer and other diseases. For such an innovative company, capital inflows into the biotech sector are crucial. This chart, reflecting overall economic confidence, influences investor willingness to fund long-term, high-risk scientific development, which is critical for Bicycle Therapeutics.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513721967 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Bicycle Therapeutics
Bicycle Therapeutics is developing a new class of drugs called "bicycles" for the treatment of cancer and other serious diseases. The company is in the clinical trial phase, which entails significant investment. This chart illustrates the investment in this innovative scientific platform with the potential to create breakthrough drugs.
Market segment marginality - Oncology platforms
Bicycle Therapeutics is developing a new class of drugs based on bicyclic peptides for the treatment of cancer and other diseases. This chart shows the average profitability in the pharmaceutical industry. Its unique technology platform, combining the advantages of small molecules and antibodies, gives the company the potential to create breakthrough drugs and achieve high profitability.
Market marginality as a whole
Bicycle Therapeutics is a biotech company developing a new class of drugs based on bicyclic peptides for the treatment of cancer and other diseases. Its financial health tells the story of its investment in science. This total profitability chart demonstrates the vast difference between its costly research at the cutting edge of medicine and the ongoing profitability of its established business.
Employees in the company, segment and market as a whole
Number of employees in the company Bicycle Therapeutics
Bicycle Therapeutics is developing a new class of drugs. Its team consists primarily of scientists and researchers. This schedule represents the investment in intellectual capital required to advance this unique therapeutic platform through all stages of drug development.
Share of the company's employees Bicycle Therapeutics within the market segment - Oncology platforms
Bicycle Therapeutics is a pioneer in developing a new class of drugs based on "bicyclic peptides," which combine the best properties of antibodies and small molecules. This is breakthrough science. This chart shows the company's concentration of exceptional scientists in this emerging field of chemistry and biology, confirming its status as a technological leader.
Number of employees in the market segment - Oncology platforms
Bicycle Therapeutics plc is a biotech company developing a new class of drugs called "bicyclic peptides." The growth of its scientific team, which can be seen in the graph, is a direct indicator of research progress. This increase in staff suggests that its unique platform is generating an increasing number of promising drug candidates.
Number of employees in the market as a whole
Bicycle Therapeutics plc is developing a new class of drugs based on bicyclic peptides. Its activities are pure science and biotechnology. The company's success depends on breakthroughs in the laboratory and clinical trials, not on the labor market, as shown in this chart. It is focused on creating fundamentally new treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Bicycle Therapeutics (BCYC)
Bicycle Therapeutics is a biotech company developing a new class of drugs. Its market capitalization is a bet on its scientific platform. This chart shows an extremely high valuation of intellectual capital. The company's entire value is attributed to its small team of scientists, resulting in a huge ratio per employee.
%20of%20the%20company%20Bicycle%20Therapeutics%20(BCYC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Bicycle-Therapeutics-BCYC&v=1772513722371 "Chart of market capitalization per employee (in thousands of dollars) of the company Bicycle Therapeutics (BCYC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology platforms
Bicycle Therapeutics is developing a new class of drugs based on bicyclic peptides. This cutting-edge biotechnology company is focused entirely on its scientific platform and research team. This chart shows the high valuation investors place on intellectual capital and R&D potential per scientist.
%20by%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-platforms&v=1772513722429 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology platforms")
Market capitalization per employee (in thousands of dollars) for the overall market
Bicycle Therapeutics is a biotech company developing a new class of drugs based on bicyclic peptides ("bicycles"). The chart illustrates the valuation of this breakthrough scientific platform. The very high market capitalization per employee reflects the enormous potential of their technology for creating drugs for cancer and other diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513722496 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Bicycle Therapeutics (BCYC)
Bicycle Therapeutics is a biotech company developing a new class of drugs called "Bicycles"—synthetic molecules for targeted therapy. This is cutting-edge science. This chart shows the cost of this R&D. It likely demonstrates significant investment (losses) per scientist working on this unique therapeutic platform.
%20Chart%20Bicycle%20Therapeutics%20(BCYC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Bicycle-Therapeutics-BCYC&v=1772513722574 "Company Profit Per Employee (in thousands of dollars) Chart Bicycle Therapeutics (BCYC)")
Profit per employee (in thousands of dollars) in the market segment - Oncology platforms
Bicycle Therapeutics (BCYC) is an R&D biotech company (oncology, "bicycle" peptides). This chart shows the benchmark for "Oncology" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of cash in the hopes of one or two mega-successes. The entire sector is an R&D race.
%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-platforms&v=1772513722584 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology platforms")
Profit per employee (in thousands of dollars) for the market as a whole
Bicycle Therapeutics (BCYC) is a clinical-stage biotech developing a new class of drugs called "Bicycles"—synthetic peptides for oncology. It is not yet profitable. This chart shows the R&D investment (loss) per scientist, which is typical for a biotech company searching for a breakthrough therapeutic platform.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513722678 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Bicycle Therapeutics (BCYC)
Bicycle Therapeutics is developing a new class of drugs based on bicyclic peptides. For a biotech company, this chart reflects success in monetizing its unique platform. Increased revenue per employee typically results from major partnerships with pharmaceutical giants.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Bicycle-Therapeutics-BCYC&v=1772513722705 "Sales chart per company employee Bicycle Therapeutics (BCYC)")
Sales per employee in the market segment - Oncology platforms
Bicycle Therapeutics (BCYC) is a clinical-stage biotech developing a new class of drugs (Bicycles)—short peptides for the treatment of cancer. The company has no approved products. This graph does not reflect their value. As with other R&D biotechs, staff productivity on this graph will be zero or very low (partner fees).
Sales per employee for the market as a whole
Bicycle Therapeutics is a biotech company developing a new class of drugs ("Bicycles"). This is a deep R&D company. During the clinical trial phase, revenue is minimal, but the R&D staff is large. This metric is important as a future indicator: if successful, it will show how effectively the company will be able to commercialize its scientific platform.
Short shares by company, segment and market as a whole
Shares shorted by company Bicycle Therapeutics (BCYC)
Bicycle Therapeutics (BCYC) is a biotech company developing a new class of drugs called "bicycles." These are small molecules linked by peptides that are designed to combine the precision of antibodies with the penetration of small molecules. This chart shows bearish bets. Skeptics doubt this new, unproven technology or the success of their oncology programs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Bicycle-Therapeutics-BCYC&v=1772513722787 "Short Shares Chart for the Company Bicycle Therapeutics (BCYC)")
Shares shorted by market segment - Oncology platforms
Bicycle Therapeutics (BCYC) is a biotech company developing a new class of drugs (bicyclic peptides) for the treatment of cancer. This chart is a barometer of sentiment across the entire biotech industry. If investors are short the sector, they are skeptical of the success of this new, albeit promising, technology, fearing failure in clinical trials.
Shares shorted by the overall market
Bicycle Therapeutics is a clinical-stage biotech with a unique oncology platform. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, unprofitable biotechs like BCYC in order to move into safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Bicycle Therapeutics (BCYC)
Bicycle Therapeutics is a biotech company developing a new drug platform (Bicycles). The stock is highly speculative. This chart can surge above 70 on positive R&D news or partnerships. The <30 zone often reflects setbacks, delays, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Bicycle-Therapeutics-BCYC&v=1772513723111 "RSI 14 indicator chart for the company's stock Bicycle Therapeutics (BCYC)")
RSI 14 Market Segment - Oncology platforms
Bicycle Therapeutics is a biopharmaceutical company developing a new class of drugs called "bicyclic peptides" (Bicycles®). This platform is used to develop targeted therapies in oncology. This chart shows the overall sentiment in the oncology platform sector. It helps separate the dynamics of BCYCs from the general "noise" in the biotech sector.
RSI 14 for the overall market
Bicycle Therapeutics (BCYC) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BCYC (Bicycle Therapeutics)
Bicycle Therapeutics (BCYC) is a biotech company developing a new class of drugs called "bicycles." These are small molecules that act like antibodies and are used to treat cancer and other diseases. This chart shows the average analyst forecast. It reflects their assessment of the potential of this unique platform and early clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BCYC-Bicycle-Therapeutics&v=1772513723495 "A chart showing analyst consensus forecasts for the expected stock price. BCYC (Bicycle Therapeutics)")
The difference between the consensus estimate and the actual stock price BCYC (Bicycle Therapeutics)
Bicycle Therapeutics is a biotech company developing a new class of drugs called Bicycles. These are small molecules that act like antibodies for cancer treatment. This chart measures the gap between the current price and the consensus target price. It shows how much confidence experts have in this innovative scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BCYC-Bicycle-Therapeutics&v=1772513723571 "A chart showing the difference between the consensus forecast and the actual stock price. BCYC (Bicycle Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology platforms
Bicycle Therapeutics is a biotech company developing a new class of drugs called "bicyclic peptides." These are the "golden mean" between small molecules (pills) and large molecules (antibodies). This chart shows general expectations for the oncology platform sector. It reflects how confident experts are in this new technology.
Analysts' consensus forecast for the overall market share price
Bicycle Therapeutics (BCYC) is a cutting-edge biotech developing a new drug platform (Bicycles) for oncology. This is a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs with revolutionary potential. Pessimism = risk aversion.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Bicycle Therapeutics
Bicycle Therapeutics is a biotech company with a unique platform. They create bicycles—a new class of drugs (peptides) that are as small as small molecules but as precise as antibodies. They focus on oncology. This chart is an assessment of their breakthrough science. It reflects the market's confidence in their bicycle technology and its ability to deliver payloads (toxins) precisely to tumors.
AKIMA Market Segment Index - Oncology platforms
Bicycle (BCYC) is a UK-based biotech pioneer developing a new class of drugs called Bicycles—small molecules that, like antibodies, can deliver toxins directly to cancer cells. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough R&D platform (Bicycles) differentiate BCYC from the average pharma company?
The AKIM Index for the overall market
Bicycle Therapeutics is a biotech company developing a new class of drugs based on "bicycle" peptides (Bicycles) for oncology. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative platform compares to the overall economic trends affecting the healthcare sector.
